SCHEMBL4771365

SCHEMBL4771365

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(N(C=O)CC(O)CO)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
CRY1 Q16526 6/20 0.37
CRY2 Q49AN0 6/20 0.37
PER2 O15055 6/20 0.37
ALDH1A1 P00352 2/20 0.36
MAPT P10636 3/20 0.35
LMNA P02545 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
GLA P06280 1/20 0.35
CYP2D6 P10635 1/20 0.35
CXCR2 P25025 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
RECQL P46063 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777347 0.88 NR1H4 (0.39) GAAALDH1A1MAPTLMNANPSR1
SCHEMBL4777314 0.86 GAA (0.38) GAACRY1CRY2PER2ALDH1A1
SCHEMBL4776590 0.83 GAA (0.42) GAACRY1CRY2ALDH1A1MAPT
SCHEMBL4777561 0.82 GAA (0.36) GAACRY1CRY2PER2ALDH1A1
SCHEMBL4775060 0.82 GAA (0.39) GAAALDH1A1MAPTLMNANPSR1
SCHEMBL4775362 0.82 GAA (0.39) GAACRY1CRY2PER2ALDH1A1
SCHEMBL5571819 0.79 SLC6A4 (0.42) GAAALDH1A1MAPTLMNACYP1A2
SCHEMBL4777570 0.78 GAA (0.43) GAACRY1CRY2PER2ALDH1A1
SCHEMBL4777644 0.77 GAA (0.45) GAAALDH1A1MAPTLMNANPSR1
SCHEMBL4777338 0.77 ALDH1A1 (0.37) GAAALDH1A1MAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885CRY1 4457/4885CRY2 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.